Patent ID: 8206714
Filing Date: 2012-06-26
Classification: A61K,A61P,C07K,Y02A,Y10S

Abstract:
1. A method for inhibiting human TNFα activity in a human subject suffering from rheumatoid arthritis comprising administering to the human subject an interleukin-17 inhibitor and an isolated human anti-TNFα antibody, or an antigen binding portion thereof, such that human TNFα activity in the human subject is inhibited, wherein the anti-TNFα antibody, or antigen binding portion thereof, dissociates from human TNFα with a K d of 1×10 −8 M or less and a K off rate constant of 1×10 −3 s −1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC 50 of 1×10 −7 M or less.